Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05390593

Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation — iTBS  

Depressive Disorder, Treatment-Resistant Clinical Trial

Official title:
Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation: a Three-track Approach in Affective Computing, Randomized Controlled Trial, and Meta-analysis

Clinical Trial Summary

The main purpose of this study is to investigate the two different intermittent Theta Burst (iTBS) repetitive transcranial magnetic stimulation (rTMS), its effectiveness in alleviating depressive symptoms. All patients are randomized to two different iTBS groups.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05390593
Study type Interventional
Source Chang Gung Memorial Hospital
Contact
Status Active, not recruiting
Phase N/A
Start date August 1, 2021
Completion date July 31, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03851380 - Improving Brain Stimulation Through Imaging
Completed NCT04977674 - Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine Early Phase 1
Completed NCT03207282 - Treatment Resistant Depression in America Latina
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02691520 - Epidemiology of Treatment Resistant Depression in Taiwan Phase 4
Active, not recruiting NCT04159012 - NESBID: Neuro-Stimulation of the Brain in Depression N/A
Recruiting NCT05870501 - Synaptic Imaging and Network Activity in Treatment Resistant Depression N/A
Completed NCT04239651 - rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) N/A
Completed NCT02493868 - A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Phase 3
Completed NCT04599855 - A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression Phase 4
Completed NCT03283670 - Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies Phase 2
Recruiting NCT03004521 - Lithium Versus Quetiapine in Treatment Resistant Depression Phase 4
Recruiting NCT04783103 - Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study N/A
Completed NCT03434041 - A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Phase 3
Terminated NCT03887624 - Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. Early Phase 1
Completed NCT02577250 - Ketamine Infusions for PTSD and Treatment-Resistant Depression Phase 1
Recruiting NCT02610712 - Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Phase 4
Completed NCT03051256 - Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD Phase 2
Enrolling by invitation NCT05581797 - Psilocybin-assisted Interpersonal Therapy for Depression N/A
Completed NCT02782104 - A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression Phase 3